Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0JQMLE
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
wO2023232144A1ADC-2
|
|||||
| Synonyms |
WO2023232144A1ADC-2
Click to Show/Hide
|
|||||
| Organization |
GeneQuantum Healthcare (Suzhou) Co. Ltd.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.8
|
|||||
| Structure |
|
|||||
| Antibody Name |
anti-HER2 antibody mAb-1
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
WO2023232144A1, ADC-2, Payload
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase I (TOP1)
|
Target Info | ||||
| Linker Name |
WO2023232144A1, ADC-2, linker
|
Linker Info | ||||
| Combination Type |
LP-6
|
|||||
ADC-specific functional property(2027 Update)
Circulating Stability
| Incubation Time | 0h | Release | 100% | Reference |
[1]
|
|---|---|---|---|---|---|
| Incubation Medium | The change rates of DAR | ||||
| Description |
When ADC-2 was incubated in healthy mixed human plasma for 0,24,48 and 96 h, the change rates of DAR were 100.00%, 106.7%, 104.2% and 106.5%, respectively. The shedding ratio of small molecular toxins was 0.006%, 0.179%, 0.373% and 1.07%, respectively.
Click to Show/Hide
|
||||
| Incubation Time | 24h | Release | 106.7% | Reference |
[1]
|
| Incubation Medium | The change rates of DAR | ||||
| Description |
When ADC-2 was incubated in healthy mixed human plasma for 0,24,48 and 96 h, the change rates of DAR were 100.00%, 106.7%, 104.2% and 106.5%, respectively. The shedding ratio of small molecular toxins was 0.006%, 0.179%, 0.373% and 1.07%, respectively.
Click to Show/Hide
|
||||
| Incubation Time | 48h | Release | 104.2% | Reference |
[1]
|
| Incubation Medium | The change rates of DAR | ||||
| Description |
When ADC-2 was incubated in healthy mixed human plasma for 0,24,48 and 96 h, the change rates of DAR were 100.00%, 106.7%, 104.2% and 106.5%, respectively. The shedding ratio of small molecular toxins was 0.006%, 0.179%, 0.373% and 1.07%, respectively.
Click to Show/Hide
|
||||
| Incubation Time | 96h | Release | 106.5% | Reference |
[1]
|
| Incubation Medium | The change rates of DAR | ||||
| Description |
When ADC-2 was incubated in healthy mixed human plasma for 0,24,48 and 96 h, the change rates of DAR were 100.00%, 106.7%, 104.2% and 106.5%, respectively. The shedding ratio of small molecular toxins was 0.006%, 0.179%, 0.373% and 1.07%, respectively.
Click to Show/Hide
|
||||
Bystander Killing Effect
| Bystander Killing Effect | Description | Reference |
|---|---|---|
| no | Undisclosed |
[1]
|
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.1076 nM | Positive ErbB2/HER2 expression (ErbB2/HER2+++/++) | ||
| Method Description |
Cytotoxicity of ADC-2 to SK-BR-3 cells
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.4355 nM | Positive ErbB2/HER2 expression (ErbB2/HER2+++/++) | ||
| Method Description |
Cytotoxicity of ADC to HCC1954 cells
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||
References